Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PT010 vs PT003 vs PT009 vs Symbicort in Moderate to Very Severe COPD (PT010006)
jRCT2080224020Phase 3
- Sponsor
- Pearl Therapeutics
- Start
- Aug 2018
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Breztri Aerosphere, BEVESPI AEROSPHERE, budesonide + formoterol fumarate and budesonide in chronic obstructive pulmonary disease (COPD) (4 arms), sponsored by Pearl Therapeutics.
02
Drugs
Breztri AerosphereBEVESPI AEROSPHEREbudesonide + formoterol fumaratebudesonide
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on jRCT2080224020.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224020.